GLP-1 drugs like Ozempic and Wegovy have already changed spending patterns in grocery aisles, restaurants, and health care. Now the focus has widened to the labor market, where a new study found a small but unusual link between these medications and work. The finding does not show that the drugs directly cause employment changes, but it does suggest they may be tied to how some people participate in jobs.
Researchers found a measurable change in labor participation
A National Bureau of Economic Research working paper released on August 26, 2024 examined labor outcomes tied to GLP-1 drug use, including Ozempic. The researchers reported that among people with obesity, taking one of these medications was associated with a roughly 1.2 percentage point increase in employment over the following year. The paper also found users worked about 0.8 more hours per week on average, according to the authors.
The study focused on adults whose obesity had previously limited their ability to work. The researchers stated that improved mobility, better health, and fewer work-limiting conditions were the most likely explanations for the employment effect. The paper did not say every user saw a job benefit, and it did not conclude that employers changed hiring rules because of Ozempic.
What is confirmed, and what is still not known
The confirmed finding is a statistical link between GLP-1 use and higher employment among a specific group of adults in the United States. The researchers used survey and health data to measure labor force participation, but they did not release a state-by-state breakdown in the paper. That means no verified list shows which local job markets saw the biggest changes.
What is also not known is whether the effect will last over several years. The paper measured outcomes over about 12 months, and long-term continuation rates for GLP-1 drugs have varied in other health research. Researchers also did not say the effect applied equally across every industry, wage level, or region.
Why this may be happening and what it means now
The paper said the most likely reason is that better weight-related health can remove barriers to work. For some adults, obesity is linked to lower stamina, chronic pain, and diabetes-related complications, all of which can affect attendance and job retention. If treatment improves those conditions, labor-force participation can rise even without any change in employer demand.
For workers and employers, the immediate takeaway is limited but notable. The study suggests these drugs may have economic effects beyond health spending, especially if more people are able to keep jobs or increase hours. Researchers said more data will be needed to confirm whether the employment effect grows, levels off, or differs by occupation as GLP-1 use expands in the U.S.
